Vertex CEO Reshma Kewalramani (L) and executive chairman Jeffrey Leiden (Erin Clark/The Boston Globe via Getty Images)
One bidder and a $5 hike: How Vertex inked $4.9B Alpine deal
Jeffrey Leiden wanted Alpine.
The Vertex chair, who had led early development of the world’s top-selling medicine while at Abbott in the 2000s, had his …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
